Edition:
India

Roche Presents Data For Hemlibra At ISTH 2019 Congress


Tuesday, 9 Jul 2019 

July 9 (Reuters) - Roche Holding AG ::NEW ANALYSES FROM PHASE III HAVEN STUDIES SUPPORT HEMLIBRA'S SUSTAINED EFFICACY, SAFETY AND QUALITY OF LIFE BENEFIT IN PEOPLE WITH HAEMOPHILIA A, WITH AND WITHOUT FACTOR VIII INHIBITORS.FIRST DATA OF PHASE IIIB STASEY STUDY REINFORCES SAFETY PROFILE OF HEMLIBRA SEEN IN PIVOTAL HAVEN 1 CLINICAL TRIAL.NEW ANALYSIS OF PIVOTAL DATA SUGGESTS ADDITIONAL FACTOR TREATMENT MAY NOT BE NEEDED FOR PEOPLE ON HEMLIBRA UNDERGOING CERTAIN MINOR SURGERY.